Cyclosporine A inhibits polymorphonuclear leukocyte chemotaxis in vivo

We have examined the effects of CsA therapy on the ability of serum and neutrophils from psoriatics to stimulate chemotaxis. No statistically significant changes were detected. The discrepancy between the in vivo and the in vitro findings cannot be explained at the moment with this small sample of patients. The depression of neutrophil function observed in vivo during treatment could be a cause or a consequence of the clearing of the psoriasis. The results clearly indicate that CsA can inhibit in vivo migration of neutrophils out of the dermal capillaries. It seems likely that this is an inflammatory effect and not a modification of neutrophil function. This antiinflammatory activity may be one of the mechanisms by which CsA therapy improves psoriasis.